U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C26H31N5O3
Molecular Weight 461.557
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AZD-0156

SMILES

CN(C)CCCOc1ccc(cn1)-c2ccc3c(c2)c4c(cn3)n(C)c(=O)n4C5CCOCC5

InChI

InChIKey=AOTRIQLYUAFVSC-UHFFFAOYSA-N
InChI=1S/C26H31N5O3/c1-29(2)11-4-12-34-24-8-6-19(16-28-24)18-5-7-22-21(15-18)25-23(17-27-22)30(3)26(32)31(25)20-9-13-33-14-10-20/h5-8,15-17,20H,4,9-14H2,1-3H3

HIDE SMILES / InChI

Molecular Formula C26H31N5O3
Molecular Weight 461.557
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
11.0 nM [IC50]
0.58 nM [IC50]
Substance Class Chemical
Created
by admin
on Sat Jun 26 16:16:23 UTC 2021
Edited
by admin
on Sat Jun 26 16:16:23 UTC 2021
Record UNII
P5T0XWC07Z
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AZD-0156
Common Name English
AZD 0156 [WHO-DD]
Common Name English
2H-IMIDAZO(4,5-C)QUINOLIN-2-ONE, 8-(6-(3-(DIMETHYLAMINO)PROPOXY)-3-PYRIDINYL)-1,3-DIHYDRO-3-METHYL-1-(TETRAHYDRO-2H-PYRAN-4-YL)-
Systematic Name English
AZD0156
Code English
Code System Code Type Description
EVMPD
SUB193594
Created by admin on Sat Jun 26 16:16:24 UTC 2021 , Edited by admin on Sat Jun 26 16:16:24 UTC 2021
PRIMARY
PUBCHEM
118502708
Created by admin on Sat Jun 26 16:16:24 UTC 2021 , Edited by admin on Sat Jun 26 16:16:24 UTC 2021
PRIMARY
CAS
1821428-35-6
Created by admin on Sat Jun 26 16:16:24 UTC 2021 , Edited by admin on Sat Jun 26 16:16:24 UTC 2021
PRIMARY
FDA UNII
P5T0XWC07Z
Created by admin on Sat Jun 26 16:16:24 UTC 2021 , Edited by admin on Sat Jun 26 16:16:24 UTC 2021
PRIMARY
Related Record Type Details
BINDER->LIGAND
BINDING
TARGET -> INHIBITOR
IC50
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Cmax PHARMACOKINETIC DOSE
PHARMACOKINETIC
ROUTE OF ADMINSTRATION
PHARMACOKINETIC
pKa CHEMICAL
Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC